Logo image of LQDA

LIQUIDIA CORP (LQDA) Stock Overview

USA - NASDAQ:LQDA - US53635D2027 - Common Stock

23.78 USD
-0.89 (-3.61%)
Last: 9/19/2025, 8:26:48 PM
24.07 USD
+0.29 (+1.22%)
After Hours: 9/19/2025, 8:26:48 PM

LQDA Key Statistics, Chart & Performance

Key Statistics
52 Week High29.94
52 Week Low9.71
Market Cap2.05B
Shares86.09M
Float72.87M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.7
PEN/A
Fwd PE116.4
Earnings (Next)11-11 2025-11-11/amc
IPO07-26 2018-07-26
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


LQDA short term performance overview.The bars show the price performance of LQDA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

LQDA long term performance overview.The bars show the price performance of LQDA in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300

The current stock price of LQDA is 23.78 USD. In the past month the price decreased by -12.86%. In the past year, price increased by 139.1%.

LIQUIDIA CORP / LQDA Daily stock chart

LQDA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 46.56 711.73B
JNJ JOHNSON & JOHNSON 17.62 424.33B
NVO NOVO-NORDISK A/S-SPONS ADR 15.54 272.83B
NVS NOVARTIS AG-SPONSORED ADR 13.89 237.97B
AZN ASTRAZENECA PLC-SPONS ADR 17.18 236.50B
MRK MERCK & CO. INC. 10.59 203.59B
PFE PFIZER INC 7.09 136.62B
SNY SANOFI-ADR 10.61 116.19B
BMY BRISTOL-MYERS SQUIBB CO 6.69 91.64B
GSK GSK PLC-SPON ADR 8.92 81.93B
ZTS ZOETIS INC 23.45 64.65B
TAK TAKEDA PHARMACEUTIC-SP ADR 51.93 47.56B

About LQDA

Company Profile

LQDA logo image Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.

Company Info

LIQUIDIA CORP

419 Davis Drive, Suite 100

Morrisville NORTH CAROLINA 27560 US

CEO: Neal Fowler

Employees: 157

LQDA Company Website

LQDA Investor Relations

Phone: 19193284400

LIQUIDIA CORP / LQDA FAQ

What is the stock price of LIQUIDIA CORP today?

The current stock price of LQDA is 23.78 USD. The price decreased by -3.61% in the last trading session.


What is the ticker symbol for LIQUIDIA CORP stock?

The exchange symbol of LIQUIDIA CORP is LQDA and it is listed on the Nasdaq exchange.


On which exchange is LQDA stock listed?

LQDA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LIQUIDIA CORP stock?

15 analysts have analysed LQDA and the average price target is 37.4 USD. This implies a price increase of 57.28% is expected in the next year compared to the current price of 23.78. Check the LIQUIDIA CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LIQUIDIA CORP worth?

LIQUIDIA CORP (LQDA) has a market capitalization of 2.05B USD. This makes LQDA a Mid Cap stock.


How many employees does LIQUIDIA CORP have?

LIQUIDIA CORP (LQDA) currently has 157 employees.


What are the support and resistance levels for LIQUIDIA CORP (LQDA) stock?

LIQUIDIA CORP (LQDA) has a support level at 13.12 and a resistance level at 23.78. Check the full technical report for a detailed analysis of LQDA support and resistance levels.


Is LIQUIDIA CORP (LQDA) expected to grow?

The Revenue of LIQUIDIA CORP (LQDA) is expected to grow by 336.74% in the next year. Check the estimates tab for more information on the LQDA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy LIQUIDIA CORP (LQDA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LIQUIDIA CORP (LQDA) stock pay dividends?

LQDA does not pay a dividend.


When does LIQUIDIA CORP (LQDA) report earnings?

LIQUIDIA CORP (LQDA) will report earnings on 2025-11-11, after the market close.


What is the Price/Earnings (PE) ratio of LIQUIDIA CORP (LQDA)?

LIQUIDIA CORP (LQDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.7).


What is the Short Interest ratio of LIQUIDIA CORP (LQDA) stock?

The outstanding short interest for LIQUIDIA CORP (LQDA) is 23.49% of its float. Check the ownership tab for more information on the LQDA short interest.


LQDA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to LQDA. When comparing the yearly performance of all stocks, LQDA is one of the better performing stocks in the market, outperforming 96.41% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LQDA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LQDA. Both the profitability and financial health of LQDA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LQDA Financial Highlights

Over the last trailing twelve months LQDA reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS decreased by -8.28% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -54.96%
ROE -931.4%
Debt/Equity 9.84
Chartmill High Growth Momentum
EPS Q2Q%-32.43%
Sales Q2Q%141.51%
EPS 1Y (TTM)-8.28%
Revenue 1Y (TTM)30.18%

LQDA Forecast & Estimates

15 analysts have analysed LQDA and the average price target is 37.4 USD. This implies a price increase of 57.28% is expected in the next year compared to the current price of 23.78.

For the next year, analysts expect an EPS growth of 2.85% and a revenue growth 336.74% for LQDA


Analysts
Analysts82.67
Price Target37.4 (57.28%)
EPS Next Y2.85%
Revenue Next Year336.74%

LQDA Ownership

Ownership
Inst Owners66.57%
Ins Owners4.23%
Short Float %23.49%
Short Ratio6.37